Gene therapy for the heart: encapsulated viruses to the rescue

Abstract

This commentary provides an in-depth analysis and perspective on the pioneering research article titled ‘Extracellular Vesicle-Encapsulated Adeno-Associated Viruses for Therapeutic Gene Delivery to the Heart’. The original study explores the innovative use of extracellular vesicle-encapsulated AAVs (EV-AAV-6 and -9) as a superior gene-delivery approach for cardiomyocytes (CMs), which not only provides increased AAV neutralizing antibody (NAb) resistance but also has implications for increased gene delivery efficacy to ischemic hearts. This study examined the efficacy of EVs isolated from the conditioned medium of AAV-6 and -9 producing HEK293T cells in combinatorial in vitro and in vivo model systems in comparison to free AAVs in the presence of the NAbs. This commentary highlights the key findings, discusses potential implications, limitations, and suggests future directions for research in this evolving field.

Keywords

Extracellular vesicle / AAVs / genetic therapy / heart diseases

References

[1] Kieserman JM,Dubey P,Feldman AM.Current landscape of heart failure gene therapy.J Am Heart Assoc2019;8:e012239 PMCID:PMC6585330

[2] Niwano K,Koitabashi N.Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats.Mol Ther2008;16:1026-32

[3] Di Bella MA.Overview and update on extracellular vesicles: considerations on exosomes and their application in modern medicine.Biology2022;11:804 PMCID:PMC9220244

[4] Sil S,Liao K.Strategies for the use of extracellular vesicles for the delivery of therapeutics.J Neuroimmune Pharmacol2020;15:422-42 PMCID:PMC7044028

[5] Chivero ET,Peeples ES.Biogenesis, physiological functions and potential applications of extracellular vesicles in substance use disorders.Cell Mol Life Sci2021;78:4849-65 PMCID:PMC10563196

[6] Cambier L,Ibrahim A.Y RNA fragment in extracellular vesicles confers cardioprotection via modulation of IL-10 expression and secretion.EMBO Mol Med2017;9:337-52 PMCID:PMC5331234

[7] Ginn SL,Alexander IE,Abedi MR.Gene therapy clinical trials worldwide to 2017: an update.J Gene Med2018;20:e3015

[8] Smith RH.Adeno-associated virus integration: virus versus vector.Gene Ther2008;15:817-22

[9] Valdmanis PN,Kay MA.rAAV-mediated tumorigenesis: still unresolved after an AAV assault.Mol Ther2012;20:2014-7 PMCID:PMC3498811

[10] Li H,Hamilton SR.Assessing the potential for AAV vector genotoxicity in a murine model.Blood2011;117:3311-9 PMCID:PMC3069673

[11] Flotte TR.Adeno-associated virus: a ubiquitous commensal of mammals.Hum Gene Ther2005;16:401-7

[12] Herzog RW,Couto LB.Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector.Nat Med1999;5:56-63

[13] Wang Z,Qiao C.Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart.Nat Biotechnol2005;23:321-8

[14] Rapti K,Kohlbrenner E.Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models.Mol Ther2012;20:73-83 PMCID:PMC3255603

[15] Naim C,Hajjar RJ.Gene therapy for heart failure: where do we stand?.Curr Cardiol Rep2013;15:333 PMCID:PMC3562543

[16] Louis Jeune V,Hajjar RJ.Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.Hum Gene Ther Methods2013;24:59-67. PMCID:PMC3732124

[17] Greenberg B,Felker GM.Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure.Gene Ther2016;23:313-9 PMCID:PMC6558655

[18] Li X,Liang Y.Extracellular vesicle-encapsulated adeno-associated viruses for therapeutic gene delivery to the heart.Circulation2023;148:405-25

[19] MacLaren RE,Barnard AR.Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial.Lancet2014;383:1129-37 PMCID:PMC4171740

[20] György B,Indzhykulian AA.Rescue of hearing by gene delivery to inner-ear hair cells using exosome-associated AAV.Mol Ther2017;25:379-91 PMCID:PMC5368844

[21] Hudry E,Gandhi S.Exosome-associated AAV vector as a robust and convenient neuroscience tool.Gene Ther2016;23:380-92 PMCID:PMC4824662

[22] Wassmer SJ,György B,Maguire CA.Exosome-associated AAV2 vector mediates robust gene delivery into the murine retina upon intravitreal injection.Sci Rep2017;7:45329 PMCID:PMC5374486

[23] György B,Crommentuijn MH,Maguire CA.Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo.Biomaterials2014;35:7598-609 PMCID:PMC4104587

[24] Maguire CA,Sivaraman S.Microvesicle-associated AAV vector as a novel gene delivery system.Mol Ther2012;20:960-71 PMCID:PMC3345986

[25] Lener T,Aigner L.Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.J Extracell Vesicles2015;4:30087 PMCID:PMC4698466

[26] Bozoglu T,Ziegler T.Endothelial retargeting of AAV9 in vivo.Adv Sci2022;9:e2103867

[27] Tabebordbar M,Stanton A.Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species.Cell2021;184:4919-38.e22 PMCID:PMC9344975